Their lead drug failed both main goals in key study, but Or­p­hazyme plans to pitch sub­group analy­ses to reg­u­la­tors

Or­p­hazyme at­tempt­ed on Wednes­day to en­thuse in­vestors about the re­sults of a Phase II/III study test­ing their lead drug, ari­mo­clo­mol, in pa­tients with a rare ge­net­ic dis­or­der, un­der­scor­ing some pos­i­tive sub­group analy­ses — even though the ex­per­i­men­tal treat­ment missed its pri­ma­ry end­points. The com­pa­ny is now prepar­ing mar­ket­ing fil­ings and plan­ning to en­gage with reg­u­la­tors to get ari­mo­clo­mol on the mar­ket at the ear­li­est.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER